文献速递胸部肿瘤放疗

立体定向体部放疗再照射治疗复发晚期非小细胞肺癌

Thoracic Reirradiation with Stereotactic Body Radiation Therapy (SBRT) for Recurrent Advanced Non-Small Cell Lung Cancer (NSCLC).
PubMed 文献 · Pract Radiat Oncol · 2024-02-21

该回顾性图表综述纳入7例既往接受放疗后肺实质复发的非小细胞肺癌患者,采用60 Gy分8次立体定向体部放疗再照射,中位随访38个月,局部控制维持4/7例(57.1%),3/7例(42.9%)发生2级毒性,1例(14.3%)发生3级肋骨/胸壁毒性,结论认为该方案安全有效。

要点

  • 7例大体积复发非小细胞肺癌患者接受60 Gy分8次再照射,局部控制维持4/7例(57.1%)。
  • 3/7例(42.9%)发生2级毒性,1例(14.3%)发生3级肋骨/胸壁毒性。
  • 中位无病间期为22.5个月(范围11-65个月)。

核心结论

  • 本研究报道60 Gy分8次立体定向体部放疗再照射对既往接受过放疗的大体积复发非小细胞肺癌可安全有效地实施。
  • 近2年的无病间期对患者生活质量和暂停全身治疗的时间具有意义。

研究设计与样本

  • 回顾性图表综述,纳入2013年7月至2020年2月期间因非小细胞肺癌肺实质复发接受挽救性立体定向体部放疗再照射的患者。
  • 再照射处方剂量为60 Gy分8次,采用立体定向体部放疗技术。
  • 共7例患者符合纳入标准,主要终点为最近一次随访或死亡时的局部控制,次要终点包括总生存、无病间期、癌症特异性生存和治疗相关毒性。

主要发现

  • 中位随访时间38个月(范围18.1-72.4),中位年龄67岁(范围63-80),中位再照射时间18.2个月(范围7.3-28.6)。
  • 再治疗中位内靶区体积57.9 cc(范围15.8-344.6),中位计划靶区体积113.6 cc(范围38.3-506.9)。
  • 局部控制维持4/7例(57.1%),2/7例(28.6%)存活,中位无病间期22.5个月(范围11-65)。
  • 3/7例(42.9%)发生2级毒性,1例(14.3%)发生3级肋骨/胸壁毒性,该例同时存在侵犯胸壁的疾病复发。

关键数值与推荐

  • 再照射处方剂量为60 Gy分8次,采用立体定向体部放疗技术。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究为回顾性图表综述。
  • 仅7例患者符合纳入标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Non-small cell lung cancer (NSCLC) local control remains suboptimal with rates around 75%. Stereotactic body radiation therapy (SBRT) is an option for isolated local recurrences of small-volume recurrences. This study investigates the safety and efficacy of 60 Gy in 8 fractions in large-volume local recurrences. METHODS AND MATERIALS: We conducted a retrospective chart review of patients treated with salvage SBRT for NSCLC lung parenchymal recurrence between July 2013 and February 2020. Reirradiation prescribed dose was 60 Gy in 8 fractions using the SBRT technique. The primary endpoint was local control at most recent follow-up or death. Secondary endpoints included overall survival, disease-free interval, cancer-specific survival, and treatment related toxicities. RESULTS: Seven patients met inclusion criteria. Median follow up time was 38 months (18.1-72.4). Median age was 67 years (63-80). Median time to reirradiation was 18.2 months (7.3-28.6). Retreatment median ITV was 57.9 cc (15.8-344.6), and PTV median was 113.6 cc (38.3-506.9). Local control was maintained in 4 of 7 patients (57.1%). Two of the 7 patients (28.6%) remained alive. Median disease-free interval was 22.5 months (11-65). Three of 7 patients (42.9%) had grade 2 toxicities. One patient (14.3%) had a grade 3 rib/chest wall toxicity with concurrent disease recurrence invading the chest wall. CONCLUSION: This study reports that SBRT of 60 Gy in 8 fractions was delivered safely and effectively to large volume recurrent NSCLC previously treated with radiation therapy. The disease-free interval of nearly 2 years is meaningful for patients' quality of life and duration of time off systemic therapy.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ross D, Chan D, Kuo E, et al. Thoracic Reirradiation with Stereotactic Body Radiation Therapy (SBRT) for Recurrent Advanced Non-Small Cell Lung Cancer (NSCLC). Pract Radiat Oncol. 2024. PMID: 38387781. doi:10.1016/j.prro.2024.02.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。